The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
FDA has approved Sarclisa (isatuximab-irfc), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
FDA has granted an investigational CD30-directed autologous chimeric antigen receptor T cell (CD30 CAR-T) therapy Regenerative Medicine Advanced Therapy designation for treatment of patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma.
FDA has granted Fast Track designation to tipifarnib for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma and nodal peripheral T-cell lymphoma with T follicular helper (TFH) phenotype.
Thermo Fisher Scientific Inc. has acquired Qiagen, a molecular diagnostics and sample preparation technology provider.
Five-year survival rates have improved for young adults with cancer, according to a studyin the Journal of the National Cancer Institute. For some cancers, however, there has been little improvement since the 1970s.
The burden of colorectal cancer is shifting to younger individuals as incidence increases in young adults and declines in older age groups, according to the latest edition of Colorectal Cancer Statistics 2020, a publication of the American Cancer Society.
The phase III BOSTON study met its primary endpoint of a statistically significant increase in progression-free survival.
The phase III KEYNOTE-204 trial evaluating Keytruda in adult patients with relapsed or refractory classical Hodgkin lymphoma met one of its dual primary endpoints of progression-free survival.
City of Hope scientists have developed and tested the first chimeric antigen receptor therapy using chlorotoxin, a component of scorpion venom, to direct T cells to target brain tumor cells, according to a preclinical study published March 4 in Science Translational Medicine. The institution has also opened the first in-human clinical trial to use the therapy.
